Cytochrome P 450 isoforms involved in melatonin metabolism in human liver microsomes
Autor: | Christer von Bahr, Mats Hidestrand, Gunnel Tybring, Gabriella Facciolà |
---|---|
Rok vydání: | 2001 |
Předmět: |
medicine.medical_specialty
Furafylline Pharmacology Hydroxylation Isozyme Substrate Specificity Melatonin chemistry.chemical_compound Cytochrome P-450 Enzyme System Internal medicine medicine Humans Pharmacology (medical) Cells Cultured Chromatography High Pressure Liquid chemistry.chemical_classification biology CYP1A2 Cytochrome P450 General Medicine Metabolism Isoenzymes Endocrinology Enzyme chemistry Fluvoxamine Microsomes Liver biology.protein Microsome Selective Serotonin Reuptake Inhibitors medicine.drug |
Zdroj: | European Journal of Clinical Pharmacology. 56:881-888 |
ISSN: | 1432-1041 0031-6970 |
DOI: | 10.1007/s002280000245 |
Popis: | Objective: The present study was carried out to identify the cytochrome P 450 enzyme(s) involved in the 6-hydroxylation and O-demethylation of melatonin. Methods: The formation kinetics of 6-hydroxymelatonin and N-acetylserotonin were determined using human liver microsomes and cDNA yeast-expressed human enzymes (CYP1A2, 2C9 and 2C19) over the substrate concentration range 1–1000 µM. Selective inhibitors and substrates of various cytochrome P 450 enzymes were also employed. Results: Fluvoxamine was a potent inhibitor of 6-hydroxymelatonin formation, giving 50±5% and 69±9% inhibition at concentrations of 1 µM and 10 µM, respectively, after incubation with 50 µM melatonin. Furafylline, sulphaphenazole and omeprazole used at low and high concentrations substantially inhibited both metabolic pathways. cDNA yeast-expressed CYP1A2, CYP2C9 and CYP2C19 catalysed the formation of the two metabolites, confirming the data obtained with specific inhibitors and substrates. Conclusions: Our results strongly suggest that 6-hydroxylation, the main metabolic pathway of melatonin, is mediated mainly, but not exclusively, by CYP1A2, the high-affinity enzyme involved in melatonin metabolism, confirming the observation that a single oral dose of fluvoxamine increases nocturnal serum melatonin levels in healthy subjects. Furthermore, the results indicate that there is a potential for interaction with drugs metabolised by CYP1A2 both at physiological levels and after oral administration of melatonin, while CYP2C19 and CYP2C9 are assumed to be less important. |
Databáze: | OpenAIRE |
Externí odkaz: |